News Conference News AHA 2025 LAAO Doesn’t Match Medical Therapy for High-risk AF Patients: CLOSURE-AF Caitlin E. Cox November 09, 2025
News Conference News AHA 2023 DAPA-MI: Cardiometabolic Endpoints ‘Win’ With Dapagliflozin After Acute MI Shelley Wood November 11, 2023
News Conference News AHA 2023 Inflammation More Powerful Than LDL as CV Risk Predictor in Statin-Free Patients Caitlin E. Cox November 07, 2023
News Conference News AHA 2022 EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD Todd Neale November 06, 2022
News Conference News AHA 2022 IRONMAN Misses but Lends Support to IV Iron Repletion in HF Shelley Wood November 05, 2022
News Conference News AHA 2021 Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE Shelley Wood November 14, 2021
News Conference News AHA 2020 Both Statins and Placebos Produce ‘Very Real’ Side Effects: SAMSON Michael O'Riordan November 15, 2020
News Conference News AHA 2019 EVAPORATE Hints at Slowed Plaque Progression With Icosapent Ethyl Todd Neale November 18, 2019
News Conference News AHA 2018 Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT Michael O'Riordan November 10, 2018
News Conference News AHA 2017 Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events Michael O'Riordan November 17, 2017